Development of an LC-MS/MS method for the simultaneous quantification of aripiprazole and dehydroaripiprazole in human plasma

Analytical Biochemistry

Volumn 385, Issue 2, 2009, Pages 270-277

  Song, Min ^a   Xu, Xinxin ^a   Hang, Taijun ^a   Wen, Aidong ^b   Yang, Lin ^b  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Aripiprazole; Dehydroaripiprazole; LC MS MS; Pharmacokinetic

Indexed keywords

LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; METABOLITES; PHARMACOKINETICS; PLASMA (HUMAN); POSITIVE IONS;

ARIPIPRAZOLE; DEHYDROARIPIPRAZOLE; ION ELECTROSPRAY IONIZATION; LC-MS/MS; LIQUID CHROMATOGRAPHY TANDEM MASS SPECTROMETRY (LC MS/MS); SELECTED REACTION MONITORING; SIMULTANEOUS DETERMINATIONS; US FOOD AND DRUG ADMINISTRATION;

ELECTROSPRAY IONIZATION;

ARIPIPRAZOLE; DEHYDROARIPIPRAZOLE; DRUG METABOLITE; PAPAVERINE; UNCLASSIFIED DRUG;

ACCURACY; ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG MONITORING; FEMALE; FOOD AND DRUG ADMINISTRATION; HUMAN; HUMAN EXPERIMENT; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETER; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; POSITIVE ION ELECTROSPRAY; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SINGLE DRUG DOSE; STANDARD; TABLET; TANDEM MASS SPECTROMETRY;

EID: 58149380400     PISSN: 00032697     EISSN: 10960309     Source Type: Journal    
DOI: 10.1016/j.ab.2008.11.027     Document Type: Article

References (11)

1. DeLeon A., Patel N.C., and Crismon M.L. Aripiprazole: a comprehensive review of its pharmacology, clinical effcacy, and tolerability. Clin. Ther. 26 (2004) 649-666
2. Lieberman J.A. Dopamine partial agonists: a new class of antipsychotic. CNS Drugs 18 (2004) 251-267
3. Mallikaarjun S., Salazar D.E., and Bramer S.L. Pharmacokinetics, tolerability, and safety of aripiprazole following multiple oral dosing in normal healthy volunteers. J. Clin. Pharmacol. 44 (2004) 179-187
4. Kubo M., Koue T., Inaba A., Takeda H., Maune H., Fukuda T., and Azuma J. Influence of itraconazole co-administration and CYP2D6 genotype on the pharmacokinetics of the new antipsychotic aripiprazole. Drug Metab. Pharmacokinet. 20 (2005) 55-64
5. Bristol-Myers Squibb/OtsuDk of America Pharmaceutical, Abilify (aripiprazole) tablets prescribing information, Revised November 2006.
6. Kubo M., Mizooku Y., Hirao Y., and Osumi T. Development and validation of an LC-MS/MS method for the metabolite, OPC-14857, in human plasma. J. Chromatogr. B 822 (2005) 294-299
7. Huang H.C., Liu C.H., Lan T.H., Hu T.M., Chiu H.J., Wu Y.C., and Tseng Y.L. Detection and quantification of aripiprazole and its metabolite, dehydroaripiprazole, by gas chromatography-mass spectrometry in blood samples of psychiatric patients. J. Chromatogr. B 856 (2007) 57-61
8. Lancelin F., Djebrani K., and Tabaouti K. Development and validation of a high-performance liquid chromatography method using diode array detection for the simultaneous quantification of aripiprazole and dehydro-aripiprazole in human plasma. J. Chromatogr. B 867 (2008) 15-19
9. Musengaa A., Saracino M.A., and Spinelli D. Analysis of the recent antipsychotic aripiprazole in human plasma by capillary electrophoresis and high-performance liquid chromatography with diode array detection. Anal. Chim. Acta 612 (2008) 204-211
10. US Department of Health and Human Services, Food and Drug Administration, Guidance for Industry: Bioanalytical Method Validation, US Department of Health and Human Services: Rockville, MD, 2001, Available from: .
11. Chinese State Food and Drug Administration, The guidance of bioavailability and bioequivalence study technique for chemistry drug in humans (no. [H] GCL2-1), 2005, Available from: .